First Impact Factor for : Endocrine, Metabolic & Immune Disorders – Drug Targets

News release date: June 23, 2016

Dubai, UAE, June 23, 2016:  Endocrine, Metabolic & Immune Disorders – Drug Targets  has obtained its first Impact Factor 1.987. The Impact Factor ranking has been awarded by Journal Citation Reports®, which are annually published by the Institute of Scientific Information, a division of Thomson Reuters. Its purpose is to offer a systematic means to critically evaluate the world’s leading journals, with quantifiable, statistical information based on citation data.

Endocrine, Metabolic & Immune Disorders – Drug Targets publishes timely reviews of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders.

For more information, please visit

Author: Bentham Science Publishers

A major STM journal publisher of more than 100 online and print journals and related print/online book series, Bentham Science answers the information needs of scientists in the fields of pharmaceutical, biomedical, medical, engineering, technology, computer and social sciences.

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: